Ibogaine's TBI gains held at 12 months

Still no control arm, and 25 of 30 veterans followed — durable, but not yet proven.

Weekly Science Digest, 6 Nov 2026 to 12 Nov 2026. 25 papers read, 10 preprints.

1. Ibogaine in TBI veterans, one year on

Ibogaine's gains in brain-injured veterans were still there at 12 months, uncontrolled.

Of 30 US special operations veterans given a single magnesium-ibogaine treatment, 25 completed follow-up at 3, 6, 9 and 12 months. Functional disability and clinician-rated PTSD, depression and anxiety stayed improved throughout.

How much weight it carries: Prospective 12-month follow-up of 30 treated veterans, 25 retained, with no control group — shows persistence, not causation. (Humans, Open-label, No control group, Small sample, n = 30)

2. Three small trials, one shared mechanism: the self

Psilocybin and MDMA trials all landed on self-relating, but only one was blinded.

In 37 patients with major depression, a single 0.215 mg/kg psilocybin dose beat placebo on depression scores and raised positive self-concept at two weeks, with the two changes correlated. Twelve MDMA-treated depressed patients improved on alexithymia and self-compassion, and 20 adults with social anxiety improved on the Liebowitz scale against a waitlist.

How much weight it carries: One double-blind placebo-controlled trial (n=37) plus two open-label studies (n=12, n=20); the open-label arms cannot separate drug from expectancy. (Humans, RCT, Double-blind, Placebo-controlled, Brain imaging, Open-label, Small sample, n = 37)

3. What separates a psychedelic from its analogue

In human cortex, hallucinogens activated Gi1 as well as Gq; non-hallucinogenic analogues only Gq.

DOI, TCB-2 and LSD engaged both pathways through 5-HT2A receptors in post-mortem prefrontal tissue. Ariadne, 2-Br-LSD and lisuride activated Gq alone at matched concentrations, with 5-HT2A knockout mouse tissue used as confirmation.

How much weight it carries: Post-mortem human cortical membrane assays with knockout-mouse confirmation; correlational with respect to subjective effects, which were not measured. (In vitro, Mice, Rats, Mechanism)

4. A mushroom that makes psilocybin and amatoxins

Galerina indica produces both psilocybin and the toxins that kill death-cap victims.

Mass spectrometry found both compound classes in the same tissue, and genomic analysis found both biosynthetic gene clusters. Phylogenetics suggests psilocybin biosynthesis arrived by horizontal gene transfer into a lineage that already made amatoxins.

How much weight it carries: Chemical and genomic characterisation of one species; says nothing about how often such mushrooms are encountered or ingested. (Peer reviewed)

5. In brief

6. In the clinic

How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)

7. On the preprint servers

How much weight it carries: Not peer reviewed. Early results that may not hold up. (Preprint)

—
Node—
Statuslive
Throughput—